Group Gp Lp Column III Purchases 35,714,284 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) major shareholder Group Gp Lp Column III purchased 35,714,284 shares of Tenaya Therapeutics stock in a transaction dated Wednesday, March 5th. The shares were bought at an average price of $0.70 per share, for a total transaction of $24,999,998.80. Following the acquisition, the insider now owns 49,313,559 shares in the company, valued at approximately $34,519,491.30. This trade represents a 262.62 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Tenaya Therapeutics Trading Down 3.2 %

TNYA traded down $0.02 on Friday, hitting $0.46. The company had a trading volume of 2,405,357 shares, compared to its average volume of 1,862,315. The firm has a market cap of $36.05 million, a P/E ratio of -0.32 and a beta of 2.83. Tenaya Therapeutics, Inc. has a 1 year low of $0.39 and a 1 year high of $6.78. The company’s fifty day moving average price is $1.17 and its 200 day moving average price is $1.92.

Analyst Ratings Changes

TNYA has been the topic of several analyst reports. Chardan Capital reiterated a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a report on Monday, February 3rd. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $17.33.

Institutional Trading of Tenaya Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. raised its holdings in Tenaya Therapeutics by 204.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after buying an additional 226,466 shares during the period. SG Americas Securities LLC grew its position in Tenaya Therapeutics by 61.9% in the 4th quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock valued at $59,000 after acquiring an additional 15,777 shares in the last quarter. State Street Corp grew its position in Tenaya Therapeutics by 0.9% in the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company’s stock valued at $2,044,000 after acquiring an additional 9,506 shares in the last quarter. Spire Wealth Management acquired a new position in Tenaya Therapeutics in the 4th quarter valued at about $53,000. Finally, Geode Capital Management LLC grew its position in Tenaya Therapeutics by 5.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock valued at $2,502,000 after acquiring an additional 66,968 shares in the last quarter. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.